Publications by authors named "R D Gosling"
Lao People's Democratic Republic (Lao PDR) has made significant progress in reducing malaria in recent years. In the Greater Mekong Subregion, forest-going is often a risk factor contributing to continuing malaria transmission. This study assessed forest-going and other potential risk factors for malaria cases in Champasak Province, Lao PDR.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigated how long malaria rapid diagnostic tests (RDT) and ultra-sensitive RDT (uRDT) remained positive after treatment in a low transmission area in Namibia, finding an average positivity duration of 42 days for RDT and 67 days for uRDT.
- - Factors such as younger age, higher initial parasite density, and persistent parasitemia were linked to longer test positivity, indicating that the usual explanations for lingering positive results, like drug resistance, did not apply.
- - These prolonged positivity durations highlight challenges in using RDTs and uRDTs for accurately identifying current infections in low transmission settings, as they might reflect residual parasite DNA rather than active infection.
Disinfectants are essential for biosecurity, preventing the persistence and spread of zoonotic pathogens on farms and subsequent human infections. In this study, transcriptomics and genomics were utilised to assess the effect of disinfectant exposure on pathogenic . The exposure of O157:H7 to sub-optimal concentrations of commonly used farm disinfectants elicited changes in both the transcriptome and genome.
View Article and Find Full Text PDFBackground: The World Health Organization 2022 malaria chemoprevention guidelines recommend providing a full course of antimalarial treatment at pre-defined intervals, regardless of malaria status to prevent illness among children resident in moderate to high perennial malaria transmission settings as perennial malaria chemoprevention (PMC) with sulfadoxine-pyrimethamine (SP). The dhps I431V mutation circulating in West Africa has unknown effect on SP protective efficacy.
Methods: This protocol is for a three-arm, parallel, double-blinded, placebo-controlled, randomised trial in Cameroon among children randomly assigned to one of three directly-observed treatment groups: (i) Group 1 (n = 450) receives daily artesunate (AS) placebo on days - 7 to -1, then active SP plus placebo amodiaquine (AQ) on day 0, and placebo AQ on days 1 and 2; (ii) Group 2 (n = 250) receives placebo AS on days - 7 to -1, then active SP and AQ on day 0, and active AQ on days 1 and 2; and (iii) Group 3 (n = 200) receives active AS on days - 7 to -1, then placebo SP on day 0 and placebo AQ on days 0 to 2.